AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CLINUVEL PHARMACEUTICALS LTD

8.010

-0.150-1.84%

Volume:180.47K

Turnover:1.45M

Market Cap:402.11M

PE:11.99

High:8.260

Open:8.170

Low:7.950

Close:8.160

52wk High:13.399

52wk Low:7.950

Shares:50.20M

Float Shares:41.32M

Volume Ratio:1.91

T/O Rate:0.44%

Dividend:0.05

Dividend Rate:0.62%

EPS(TTM):0.668

EPS(LYR):0.668

ROE:13.21%

ROA:8.94%

PB:1.47

PE(LYR):11.99

Loading ...

Overview Company News Filings

ASX Growth Companies With Insider Ownership Up To 38%

Simply Wall St.

Exploring Appen And 2 Promising Tech Stocks With High Growth Potential

Simply Wall St.

Clinuvel Pharmaceuticals; Parmantier & Cie. sets AUD 24 price target, reiterates Buy

ASX 300 healthcare stock outperforming today on 'strategic' leadership news

Clinuvel Pharmaceuticals Retains Philippe Wolgen as CEO

MT Newswires Live

Clinuvel Pharmaceuticals Ltd-Chair Letter to Shareholders

THOMSON REUTERS

Clinuvel Pharmaceuticals - We Expect That Nasdaq Listing for a Level Ii Adr May Be Possible in the First Half of This Year

THOMSON REUTERS

Clinuvel Pharmaceuticals Ltd - Philippe Wolgen to Continue as CEO

THOMSON REUTERS

Morgans says these small-cap ASX shares could rise 30% to 80%

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/CUV.AU/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CUV.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CUV.AU\",,,,,undefined,":{"symbol":"CUV.AU","market":"AU","secType":"STK","nameCN":"CLINUVEL PHARMACEUTICALS LTD","latestPrice":8.01,"timestamp":1789020720000,"preClose":8.16,"halted":0,"volume":180467,"delay":0,"changeRate":-0.018382352941176513,"nameEN":"CLINUVEL PHARMACEUTICALS LTD","floatShares":41318955,"shares":50200740,"eps":0.667999,"marketStatus":"Not Yet Opened","change":-0.15,"latestTime":"09-10 16:12:00 AEST","open":8.17,"high":8.26,"low":7.95,"amount":1450513,"amplitude":0.03799,"askPrice":8.1,"askSize":535,"bidPrice":8,"bidSize":732,"shortable":3,"etf":0,"ttmEps":0.667999,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789084800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":8.16,"dividendRate":0.006242,"openAndCloseTimeList":[[1788998400000,1789020000000]],"volumeRatio":1.9107955868962154,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CUV.AU","preClose":8.16,"auctionPrice":8.01,"auctionVolume":9316,"auction":3,"marketStatus":"盘后竞价","timestamp":1789020604080}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CUV.AU\",,,,,undefined,":{"symbol":"CUV.AU","floatShares":41318955,"roa":"8.94%","roe":"13.21%","lyrEps":0.667999,"volumeRatio":1.9107955868962154,"shares":50200740,"dividePrice":0.05,"high":8.26,"amplitude":0.03799,"preClose":8.16,"low":7.95,"week52Low":7.95,"pbRate":"1.47","psRate":"4.28","week52High":13.399,"institutionHeld":0,"latestPrice":8.01,"committee":0.155485,"eps":0.667999,"divideRate":0.006242,"volume":180467,"delay":0,"ttmEps":0.667999,"open":8.17,"prevYearClose":12.385,"prevWeekClose":8.15,"prevMonthClose":7.972,"prevQuarterClose":10.219,"fiveDayClose":8.26,"twentyDayClose":9.533,"sixtyDayClose":9.871,"dividendPayoutRate":0.07372445631899688,"dividendFrequency":"A","dividendGrowthYears":6,"dividendGrowthRate":0,"fiveYearAvgDividendRate":0.0033959070154716284},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CUV.AU\",params:#limit:5,,,undefined,":[{"date":"2026-09-03","symbol":"CUV.AU","amount":0.05,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-09-04","defaultRemindTime":1788393600000,"name":"CLINUVEL PHARMACEUTICALS LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-18","payableDate":"2026-09-04","currency":"AUD","dateTimestamp":1788357600000,"payDate":"2026-09-18"},{"date":"2026-08-27","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787788800000,"name":null,"time":"","dateTimestamp":1787752800000,"actualEps":null},{"date":"2026-02-26","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1772060400000,"name":null,"time":"","dateTimestamp":1772024400000,"actualEps":null},{"date":"2025-09-04","symbol":"CUV.AU","amount":0.05,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-09-05","defaultRemindTime":1756944000000,"name":"CLINUVEL PHARMACEUTICALS LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-19","payableDate":"2025-09-05","currency":"AUD","dateTimestamp":1756908000000,"payDate":"2025-09-19"},{"date":"2025-08-28","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756339200000,"name":null,"time":"","dateTimestamp":1756303200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CUV.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-03","recordDate":"2020-09-04","paymentDate":"2020-09-18","value":0.025,"currency":"AUD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-17","value":0.025,"currency":"AUD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-09-21","value":0.04,"currency":"AUD"},{"executeDate":"2023-09-05","recordDate":"2023-09-06","paymentDate":"2023-09-20","value":0.05,"currency":"AUD"},{"executeDate":"2024-09-05","recordDate":"2024-09-06","paymentDate":"2024-09-20","value":0.05,"currency":"AUD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CUV.AU\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622895939","title":"ASX Growth Companies With Insider Ownership Up To 38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622895939","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622895939?lang=en_us&edition=fundamental","pubTime":"2026-03-27 03:08","pubTimestamp":1774552107,"startTime":"0","endTime":"0","summary":"As the Australian stock market experiences a modest rise amidst geopolitical uncertainties, investors are keeping a close watch on sectors poised for growth and resilience. In such an environment, companies with high insider ownership often attract attention due to the confidence they signal in their own potential, making them intriguing prospects for those seeking long-term growth opportunities.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-companies-with-insider-ownership-up-to-38-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-companies-with-insider-ownership-up-to-38-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","AV1.AU","BK7016","TLX.AU","BK4531","AEM.AU","AR1.AU","MAU.AU","IQ","BK7113","TOR.AU","BK7007","FEX.AU","CYC.AU","BK7067","BK7017","TLX","BK7129","CUV.AU","FRS.AU","BK7104","BK4526","BK4552","BK7095","BK7508","BK7110","BK4505","EIQ.AU","BK4108","REG.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622895958","title":"Exploring Appen And 2 Promising Tech Stocks With High Growth Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2622895958","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622895958?lang=en_us&edition=fundamental","pubTime":"2026-03-27 03:05","pubTimestamp":1774551958,"startTime":"0","endTime":"0","summary":"Amidst a cautiously optimistic Australian market, with the ASX 200 showing modest gains due to ongoing geopolitical uncertainties, investors are keeping a close eye on sectors poised for growth despite the broader sentiment. In this environment, high-growth tech stocks like Appen and others can be particularly appealing as they offer potential for significant returns by leveraging innovative solutions and adapting swiftly to changing market dynamics.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/8031000-choice2-main-header/1585186598236","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8031000-choice2-main-header/1585186598236"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/software/asx-apx/appen-shares/news/exploring-appen-and-2-promising-tech-stocks-with-high-growth","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/software/asx-apx/appen-shares/news/exploring-appen-and-2-promising-tech-stocks-with-high-growth","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","APX.AU","BK4528","BK7016","BK4023","AIPO","BK7503","CUV.AU","FCL.AU","BK4585","BK7061","BK4588","BK4587","BK4551","AI","AIYY","BK4543","AGIX","CHAT","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622852860","title":"Clinuvel Pharmaceuticals; Parmantier & Cie. sets AUD 24 price target, reiterates Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2622852860","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622852860?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:46","pubTimestamp":1774525563,"startTime":"0","endTime":"0","summary":"Parmantier & Cie. initiated an update on Clinuvel with a Buy recommendation and a 12-month target price of AUD 24.Analysts Thomas Schiessle and Daniel Grojohann cited revenue growth of 4% and an OPEX increase of 22%.EPS was reported down 26% alongside higher development-related spending.NEURACTHEL Instant  was described as a planned second revenue source with potential of USD 150 million.Philippe Wolgen was expected to continue as CEO, and a Nasdaq Level II ADR uplisting was described as in progress.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clinuvel Pharmaceuticals Limited published the original content used to generate this news brief via EQS News, a service of EQS Group AG , on March 26, 2026, and is solely responsible for the ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL9k833R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CUV.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620277043","title":"ASX 300 healthcare stock outperforming today on 'strategic' leadership news","url":"https://stock-news.laohu8.com/highlight/detail?id=2620277043","media":"MotleyFool","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620277043?lang=en_us&edition=fundamental","pubTime":"2026-03-20 08:00","pubTimestamp":1773964847,"startTime":"0","endTime":"0","summary":"Over the past 12 months, shares in the ASX 300 healthcare stock have slumped 20% Addressing that decline, Rosenfeld said, \"Market data tell a clear story: pre-revenue biotechs often outperform as perception and hope dominates investment decisions, while profitable companies executing quietly can be undervalued.\" He added: The board, market analysts, and sophisticated institutions recognise that our share price does not reflect the company's performance. It reflects a perceived ceiling on further growth. Our job, and Philippe's, is to break through that ceiling.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/20/asx-300-healthcare-stock-outperforming-today-on-strategic-leadership-news/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/20/asx-300-healthcare-stock-outperforming-today-on-strategic-leadership-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["CUV.AU","BK7508","BK7067","XKO.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620277689","title":"Clinuvel Pharmaceuticals Retains Philippe Wolgen as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2620277689","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620277689?lang=en_us&edition=fundamental","pubTime":"2026-03-20 07:29","pubTimestamp":1773962952,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  confirmed that Philippe Wolgen will remain chief executive, citing his scientific expertise, regulatory experience, and steady leadership as vital for guiding the company through its key growth phase, according to a Friday Australian bourse filing.The company's shares were up 1% in recent Friday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","CUV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620927483","title":"Clinuvel Pharmaceuticals Ltd-Chair Letter to Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2620927483","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620927483?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:30","pubTimestamp":1773955855,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nTUE9D6FZ6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","CUV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620274866","title":"Clinuvel Pharmaceuticals  - We Expect That Nasdaq Listing for a Level Ii Adr May Be Possible in the First Half of This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2620274866","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620274866?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:30","pubTimestamp":1773955855,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nTUE9D6FZ6:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","CUV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620027485","title":"Clinuvel Pharmaceuticals Ltd - Philippe Wolgen to Continue as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2620027485","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620027485?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:30","pubTimestamp":1773955855,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nTUE9D6FZ6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","CUV.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620027294","title":"Morgans says these small-cap ASX shares could rise 30% to 80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620027294","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620027294?lang=en_us&edition=fundamental","pubTime":"2026-03-18 08:57","pubTimestamp":1773795437,"startTime":"0","endTime":"0","summary":"Having some exposure to the small side of the market can be a good thing for a balanced portfolio, if your risk tolerance allows for it.After all, the potential returns from small-cap ASX shares can be significantly greater than those on offer with large caps.With that in mind, here are two small-cap shares that Morgans thinks could rise strongly from current levels. Let's see what it is recommending:. This biopharmaceuticals company disappointed Morgans during the first half, with softer-than-expected revenue growth and higher-than-expected cost growth.However, the broker remains positive, especially given that this small-cap ASX share trades on lower-than-normal multiples.As a result, the broker has put a speculative buy rating and $13.00 price target on its shares. This implies potential upside of 30% for investors from current levels. It said:. Whilst we downgrade our FY26-17 EBITDA forecasts by 10-20% reflecting revised guidance, given RDY's robust pipeline, potential catalysts , ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/18/morgans-says-these-small-cap-asx-shares-could-rise-30-to-80/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/18/morgans-says-these-small-cap-asx-shares-could-rise-30-to-80/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["CUV.AU","BK7067","BK7508","RDY.AU","BK7016"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":5,"totalSize":89,"code":"91000000","status":"200"}]}}